GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (LSE:MEDU) » Definitions » 12-1 Month Momentum %

Aevi Genomic Medicine (LSE:MEDU) 12-1 Month Momentum % : N/A% (As of May. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Aevi Genomic Medicine 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-27), Aevi Genomic Medicine's 12-1 Month Momentum % is N/A%.

The industry rank for Aevi Genomic Medicine's 12-1 Month Momentum % or its related term are showing as below:

LSE:MEDU's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -25.61
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Aevi Genomic Medicine's 12-1 Month Momentum %

For the Biotechnology subindustry, Aevi Genomic Medicine's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aevi Genomic Medicine's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's 12-1 Month Momentum % falls into.



Aevi Genomic Medicine  (LSE:MEDU) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aevi Genomic Medicine  (LSE:MEDU) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Aevi Genomic Medicine 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aevi Genomic Medicine (LSE:MEDU) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.

Aevi Genomic Medicine (LSE:MEDU) Headlines

No Headlines